Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Omar Syed

Pain Medicine Glendale, AZ Medical Doctor

NPI 1902165046 CMS profile 3496916

6320A W Union Hills Dr Ste 270, Ste A270, Glendale, AZ 85308

Open in the dashboard

General payments

$9,724

274 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Omar Syed of Glendale, AZ is reported in the CMS Open Payments database as having received $9,724 across 274 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,565 55
2024 General $1,502 37
2023 General $914 44
2022 General $1,772 38
2021 General $2,777 42
2020 General $597 25
2019 General $598 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Omar Syed
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Omar Syed were reported at $1,565. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Omar Syed Pain Medicine median Middle half National median
2019 $598 $506 $144–$1,566 $163
2020 $597 $315 $96–$934 $114
2021 $2,777 $452 $134–$1,237 $132
2022 $1,772 $475 $124–$1,407 $149
2023 $914 $480 $136–$1,384 $160
2024 $1,502 $521 $164–$1,511 $164
2025 $1,565 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,939 52 payments
  2. Medtronic, Inc. $1,795 63 payments
  3. Nevro Corp. $1,256 57 payments
  4. Boston Scientific Corporation $991 19 payments
  5. SI-BONE, Inc. $439 3 payments
  6. Globus Medical, Inc. $417 16 payments
  7. NuVasive, Inc. $307 2 payments
  8. Nalu Medical, Inc. $238 8 payments
  9. Medtronic USA, Inc. $234 7 payments
  10. Providence Medical Technology, Inc. $146 1 payment
  11. Other $962 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,234 271 payments
  2. Travel and Lodging $448 1 payment
  3. Education $42 2 payments
Products named General payments · program years 2019–2025
  1. Proclaim IPG $1,347 15 payments
  2. INTELLIS ADAPTIVESTIM $1,102 33 payments
  3. Senza $620 26 payments
  4. PROCLAIM $606 6 payments
  5. Omnia $540 24 payments
  6. Octrode SCS Leads $463 10 payments
  7. Superion $448 1 payment
  8. KYPHON EXPRESS II KYPHOPAK TRAY $409 22 payments
  9. XLIF $307 2 payments
  10. Pulse $259 1 payment
  11. Other $3,088 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

779

Median for Anesthesiology: 322

Drug cost

$8,502

Median for Anesthesiology: $8,738

Branded share of claims

19.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 229 $1,947
Methocarbamol Generic 129 $1,737
Pregabalin Generic 82 $1,520
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 85 $1,250
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 69 $1,017
Methylprednisolone Generic 35 $242
Tizanidine Hcl Generic 43 $237
Oxycodone Hcl Generic 18 $198
Diclofenac Sodium Generic 11 $185
Tramadol Hcl Generic 78 $171

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$393,756

Medicare's payments for the services billed

Medicare patients

524

Average age 74

Services billed

3,808

296 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Chronic kidney disease 32%
Ischemic heart disease 30%
Depression 25%
Osteoporosis 23%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record